1 not yet recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Shanghai NK Cell Technology Co., LTD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC PD-1 antibody, NK010 - Resectable Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 10 | 2026-01-20 | 2026-01-06 |
| A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors NK042, Fludarabine (FLU), Cyclophosphamide (CTX) - Advanced Solid Tumors | Phase 1 | Recruiting | Shanghai NK Cell Technology Co., LTD | 76 | 2025-02-07 | 2026-04-06 |
Carcinoma, Non-Small-Cell Lung (1)
Cyclophosphamide (1) · fludarabine (1) · spartalizumab (1)
China (2)